{"id":477154,"date":"2020-04-01T11:44:02","date_gmt":"2020-04-01T11:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477154"},"modified":"2020-04-01T11:44:02","modified_gmt":"2020-04-01T11:44:02","slug":"huntingtons-disease-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/huntingtons-disease-pipeline-insight-2020_477154.html","title":{"rendered":"Huntington&#8217;s Disease Pipeline Insight, 2020"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585722504.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Huntington\\'s Disease Pipeline Insight, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585722504.png\" alt=\"Huntington\\'s Disease Pipeline Insight, 2020\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on Huntington&#8217;s Disease Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Huntington&#8217;s Disease Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Huntington&#8217;s Disease&nbsp;market. A detailed picture of the&nbsp;Huntington&#8217;s Disease&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Huntington&#8217;s Disease&nbsp;treatment guidelines. The assessment part of the report embraces in-depth&nbsp;Huntington&#8217;s Disease&nbsp;commercial assessment and clinical assessment of the&nbsp;Huntington&#8217;s Disease&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Huntington&#8217;s Disease&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">Huntington&rsquo;s disease is a hereditary neurodegenerative disorder caused by mutation in the HTT genes. The HTT mutation that causes Huntington disease involves a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/e72ddae76e2d6f6bdb02d2f18f77881b.JPG\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><em><strong>Request for :- <\/strong><\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/huntingtons-disease-pipeline-insight\" target=\"_blank\">Pipeline free sample page<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Huntington&#8217;s Disease of&nbsp;pipeline development activities&nbsp;<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">All of the companies that are developing therapies for the treatment of&nbsp;Huntington&#8217;s Disease&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li class=\"ql-align-justify\">Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;Huntington&#8217;s Disease&nbsp;treatment.<\/li>\n<li class=\"ql-align-justify\">Huntington&#8217;s Disease&nbsp;key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li class=\"ql-align-justify\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li class=\"ql-align-justify\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;Huntington&#8217;s Disease&nbsp;market.<\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>&nbsp;Huntington&#8217;s Disease&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">In-depth Huntington&#8217;s Disease Commercial Assessment of products&nbsp;<\/li>\n<\/ul>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">Huntington&#8217;s Disease Clinical Assessment of products&nbsp;<\/li>\n<\/ul>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p class=\"ql-align-justify ql-indent-1\" style=\"text-align: justify;\"><strong>&nbsp;Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;Huntington&#8217;s Disease&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Huntington&#8217;s Disease&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li class=\"ql-align-justify\">It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Huntington&#8217;s Disease&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li class=\"ql-align-justify\">Detailed&nbsp;Huntington&#8217;s Disease&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Huntington&#8217;s Disease.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em><strong>Major key companies are working on Huntington&#8217;s Disease which are given below:-<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><em><strong>1. <\/strong>ROCHE Pharma Co.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><em>2. EIP Pharma Co.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Name of covered drugs are given below:-&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1.<\/strong>&nbsp;RG6042 (RO7234292)<\/p>\n<p style=\"text-align: justify;\">2.&nbsp;&nbsp;Neflamapimod<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight#curriculum\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Huntington&#8217;s Disease&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1. Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2. History&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3. Huntington&#8217;s Disease Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6. Huntington&#8217;s Disease Diagnosis&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.1. Diagnostic Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Huntington&#8217;s Disease&nbsp;Current Treatment Patterns<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Huntington&#8217;s Disease Treatment Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Huntington&#8217;s Disease&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6. Huntington&#8217;s Disease Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\"><span>7. Huntington&#8217;s Disease Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Huntington&#8217;s Disease Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Huntington&#8217;s Disease&nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14. Huntington&#8217;s Disease&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\"><span>15. Huntington&#8217;s Disease&nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Dormant Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1.1. Reasons for being dormant<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2. Discontinued Products&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2.1. Reasons for the discontinuation<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Huntington&#8217;s Disease&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Huntington&#8217;s Disease&nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Huntington&#8217;s Disease&nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.2. Expert Panel Validation&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22. <strong>About <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">Delveinsight&nbsp;<\/a><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>Related&nbsp; Reports:<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">1.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-epidemiology-forecast\">Huntington&#8217;s Disease &#8211; Epidemiology Forecast to 2030<\/a><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">2.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington&#8217;s Disease- Market Insight, Epidemiology and Market Forecast -2030<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=huntingtons-disease-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=huntingtons-disease-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; DelveInsight has launched a new report on Huntington&#8217;s Disease Market Insights, Epidemiology and Market Forecast-2030 &#8220;Huntington&#8217;s Disease Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Huntington&#8217;s Disease&nbsp;market. A detailed &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/huntingtons-disease-pipeline-insight-2020_477154.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,420],"tags":[],"class_list":["post-477154","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477154"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477154\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}